Breaking News

APEIRON Biologics Initiates Phase II COVID-19 Trial

APN01 has potential to block infection of cells by COVID-19 virus and reduce lung injury

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

APEIRON Biologics AG received regulatory approvals in Austria, Germany and Denmark to initiate a Phase II trial of APN01 to treat COVID-19. APN01 is the recombinant form of the human angiotensin-converting enzyme 2 (rhACE2), and has the potential to block the infection of cells by the novel SARS-CoV-2 virus, and reduce lung injury. The Phase II trial aims to treat 200 severely infected COVID-19 patients. APN01 has a unique dual mode of action. APN01 imitates the human enzyme ACE2, which is us...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters